A PHASE 1/2 OPEN-LABEL DOSE-ESCALATION SAFETY AND TOLERABILITY STUDY OF NC410 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS

Go Back to All Clinical Trials

A PHASE 1/2 OPEN-LABEL DOSE-ESCALATION SAFETY AND TOLERABILITY STUDY OF NC410 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS

Brief description of study

The purpose of the study is to determine the safety and tolerability of NC410, and to assess the preliminary efficacy of NC410 in subjects with advanced or metastatic solid tumors. We want to know the maximum tolerated dose of the study drug NC410. The study drug NC410 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.

Clinical Study Identifier: s20-01658

ClinicalTrials.gov Identifier: NCT04408599

Principal Investigator: Elaine Shum.

Other Investigators: Elise M Zahriah, Janice Mehnert, Keriann M Scavone, Douglas K Marks, David R. Wise, Avital Benson, Kristen Spencer, Jessica Wang, Kathleen M Madden, Maryann J Kwa, Nila Theresa De La Rosa, Nina Beri, Salman Rafi Punekar, Jeffrey S. Weber, Ann M Riccobene, Nora Russo, Zujun Li, Joshua K Sabari, Maya Dimitrova, Vamsidhar Velcheti.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies